Effect of silymarin on lipid profile and glycemic control in patients with type 2 diabetes mellitus.
FBS
HbA1c
lipid profile
silymarin
type 2 diabetes
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
revised:
25
02
2024
received:
17
04
2023
accepted:
07
06
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
This randomized clinical trial was conducted to evaluate the effects of silymarin supplementation on glycemic indices and serum lipid profile in type 2 diabetes mellitus (T2DM) patients. In this open-label randomized clinical trial study, 48 patients with T2DM were eligible to participate for 12 weeks and were divided into two groups randomly: 24 subjects in the intervention (received three 140 mg silymarin capsules daily and diet plan) and 24 in control (received a diet plan). Fasting blood samples and anthropometric data were collected, and glycemic indices and lipid profiles were determined at baseline and at the end of the study. Out of 60 patients included in the clinical trial, 48 people completed the study. In comparing silymarin and control groups before and after the study, a significant reduction was observed in weight and body mass index. However, after adjustment, no significant difference was seen between the two groups. Furthermore, daily consumption of three capsules of 140 mg silymarin for 12 weeks did not show any significant difference on the level of fasting blood sugar (p = 0.789), HbA1c (p = 0.719), and lipid profile. The findings of the present study show that silymarin did not lead to changes in the level of glycemic index and lipid profile in patients with T2DM.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Alkuraishy, H. M., & Alwindy, S. (2012). Beneficial effects of silymarin on lipid profile in hyperlipidemic patients: Placebo controlled clinical trial. WebmedCentral Pharmacology, 3(2), WMC002966.
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Kuriakose, K. (2017). Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Frontiers in Endocrinology, 8, 6.
Chu, C., Li, D., Zhang, S., Ikejima, T., Jia, Y., Wang, D., & Xu, F. (2018). Role of silibinin in the management of diabetes mellitus and its complications. Archives of Pharmacal Research, 41(8), 785–796. https://doi.org/10.1007/s12272-018-1047-x
de Avelar, C. R., Pereira, E. M., de Farias Costa, P. R., de Jesus, R. P., & de Oliveira, L. P. M. (2017). Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta‐analysis. World Journal of Gastroenterology, 23(27), 5004–5017.
Ebrahimpour, K. S., & Pourghassem, G. B. (2014). Effects of silymarin supplementation on anthropometric indices, blood pressure and serum HS‐CRP levels in patients with type 2 diabetes mellitus: A triple‐blind randomized placebo‐controlled clinical trial, 1(1), 99.
Elgarf, A. T., Mahdy, M. M., & Sabri, N. A. (2015). Effect of silymarin supplementation on glycemic control, lipid profile and insulin resistance in patients with type 2 diabetes mellitus. International Journal, 3(12), 812–821.
Gargari, B. P., Mobasseri, M., Valizadeh, H., & Asghari‐Jafarabadi, M. (2015). Effects of Silybum marianum (L.) Gaertn.(silymarin) extract supplementation on antioxidant status and hs‐CRP in patients with type 2 diabetes mellitus: A randomized, triple‐blind, placebo‐controlled clinical trial. Phytomedicine, 22(2), 290–296.
Golestaneh, E., Aslani, A., Aghaei, M., Hashemnia, M., & Aarabi, M. H. (2021). Preparation and characterisation of a new form of silymarin as a potential antidiabetic agent in the adult male rat. Archives of Physiology and Biochemistry, 129, 799–809.
Hadi, A., Pourmasoumi, M., Mohammadi, H., Symonds, M., & Miraghajani, M. (2018). The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis of clinical trials. Complementary Therapies in Medicine, 41, 311–319.
Henriksen, E. J., Diamond‐Stanic, M. K., & Marchionne, E. M. (2011). Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radical Biology and Medicine, 51(5), 993–999.
Huseini, H. F., Larijani, B., Heshmat, R., Fakhrzadeh, H., Radjabipour, B., Toliat, T., & Raza, M. (2006). The efficacy of Silybum marianum (L.) Gaertn.(silymarin) in the treatment of type II diabetes: A randomized, double‐blind, placebo‐controlled, clinical trial. Phytotherapy Research, 20(12), 1036–1039.
Hussain, S. A.‐R. (2007). Silymarin as an adjunct to glibenclamide therapy improves long‐term and postprandial glycemic control and body mass index in type 2 diabetes. Journal of Medicinal Food, 10(3), 543–547.
Khan, M., & Siddiqui, M. (2010). Do supplements of Silybum marianum significantly lower fasting blood glucose (FBG) in patients with type II diabetes mellitus?–A suggested protocol, 10(1), 24–28.
Li, W., Zheng, H., Bukuru, J., & De Kimpe, N. (2004). Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. Journal of Ethnopharmacology, 92(1), 1–21.
Martinelli, T., Whittaker, A., Benedettelli, S., Carboni, A., & Andrzejewska, J. (2017). The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway. Phytochemistry, 144, 9–18.
Masoodi, M., Rezadoost, A., Panahian, M., & Vojdanian, M. (2013). Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases. Govaresh, 18(3), 181–185.
Mohammadi, S., Afkhami Ardacani, M., Salami, M., & Bolurani, S. (2013). Effects of silymarin on insulin resistance and blood lipid profile in first‐degree relatives of type 2 diabetic patients. Journal of Medicinal Plants, 12(46), 170–176.
Ni, X., & Wang, H. (2016). Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). American Journal of Translational Research, 8(2), 1073.
Roozbeh, J., Shahriyari, B., Akmali, M., Vessal, G., Pakfetrat, M., Raees Jalali, G. A., Afshariani, R., Hasheminasab, M., & Ghahramani, N. (2011). Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Renal Failure, 33(2), 118–123.
Sayin, F. K., Buyukbas, S., Basarali, M. K., Alp, H., Toy, H., & Ugurcu, V. (2016). Effects of Silybum marianum extract on high‐fat diet induced metabolic disorders in rats. Polish Journal of Food and Nutrition Sciences, 66(1), 43.
Škottová, N., Kazdová, L., Oliyarnyk, O., Večeřa, R., Sobolová, L., & Ulrichová, J. (2004). Phenolics‐rich extracts from Silybum marianum and Prunella vulgaris reduce a high‐sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. Pharmacological Research, 50(2), 123–130.
Soto, C., Raya, L., Juárez, J., Pérez, J., & González, I. (2014). Effect of SILYMARIN in Pdx‐1 expression and the proliferation of pancreatic β‐cells in a pancreatectomy model. Phytomedicine, 21(3), 233–239.
Soto, C. P., Perez, B. L., Favari, L. P., & Reyes, J. L. (1998). Prevention of alloxan‐induced diabetes mellitus in the rat by silymarin. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 119(2), 125–129.
Stolf, A. M., Campos Cardoso, C., Morais, H., Alves de Souza, C. E., Lomba, L. A., Brandt, A. P., Agnes, J. P., Collere, F. C., Galindo, C. M., Corso, C. R., Spercoski, K. M., Locatelli Dittrich, R., Zampronio, A. R., Cadena, S. M. S. C., & Acco, A. (2018). Effects of silymarin on angiogenesis and oxidative stress in streptozotocin‐induced diabetes in mice. Biomedicine & Pharmacotherapy, 108, 232–243. https://doi.org/10.1016/j.biopha.2018.09.042
Stolf, A. M., Cardoso, C. C., & Acco, A. (2017). Effects of silymarin on diabetes mellitus complications: A review. Phytotherapy Research, 31(3), 366–374. https://doi.org/10.1002/ptr.5768
Tajmohammadi, A., Razavi, B. M., & Hosseinzadeh, H. (2018). Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytotherapy Research, 32(10), 1933–1949. https://doi.org/10.1002/ptr.6153
Velussi, M., Cernigoi, A. M., Dapas, F., Caffau, C., & Zilli, M. (1997). Long‐term (23 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology, 26(4), 871–879.
Vidimce, J., Pennell, E. N., Foo, M., Shiels, R. G., Shibeeb, S., Watson, M., & Bulmer, A. C. (2021). Effect of silymarin treatment on circulating bilirubin and cardiovascular disease risk factors in healthy men: A single‐Blind, randomized crossover trial. Clinical Pharmacology in Drug Development, 10(10), 1156–1165.
Voroneanu, L., Nistor, I., Dumea, R., Apetrii, M., & Covic, A. (2016). Silymarin in type 2 diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials. Journal of Diabetes Research, 2016, 5147468.
World Health Organization. (2006). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation. World Health Organization.
Yao, J., Zhi, M., & Minhu, C. (2011). Effect of silybin on high‐fat‐induced fatty liver in rats. Brazilian Journal of Medical and Biological Research, 44, 652–659.